Sun Life (SLF) Q2 2026 earnings review
Diversification Pays Off as U.S. Business Reverses Course
Sun Life delivered a robust Q2 2026, with underlying net income accelerating to $1.12B (+11% YoY) and underlying EPS jumping 13% to $2.02. The narrative of a diversified model shielding the company from isolated shocks played out perfectly. The U.S. segment, which was a massive drag in late 2025 due to medical stop-loss mispricing, is officially reversing course, posting 15% earnings growth. However, beneath the strong top-line sales growth in Asia, margin compression is emerging, and massive retail outflows continue to bleed the MFS asset management arm. Reported net income was highly volatile over the last year due to acquisition charges and market impacts, but underlying earnings show a remarkably stable trajectory.
🐂 Bull Case
The 17% price hikes implemented in the U.S. stop-loss business during the 2025 renewal cycle are flowing through to the bottom line. U.S. underlying net income reversed from negative growth in Q3 2025 to a solid +15% YoY growth this quarter.
Canada is accelerating, with asset management and wealth sales surging 60% YoY to $7B. This is driven by large case defined contribution sales and increased rollover volumes, cementing the domestic fortress.
🐻 Bear Case
Despite a 19% surge in Asia individual insurance sales, New Business CSM actually fell 7% due to intense competition in Hong Kong, indicating that top-line growth is coming at the expense of future profit margins.
MFS continues to face structural headwinds, with retail net outflows accelerating to US$13.7B in the quarter (up from US$5.9B a year ago). Equity market gains masked the underlying flow bleed.
⚖️ Verdict: 🟢
Bullish. Management proved they can diagnose and fix a broken segment (U.S. Stop-Loss) within a few quarters while relying on their diversified platform (Canada, Asia) to maintain double-digit EPS growth.
Key Themes
U.S. Stop-Loss Reversing to Positive
The primary concern from late 2025 has been successfully neutralized. U.S. underlying net income grew 15% to US$164 million. Management's aggressive repricing strategy (taking 17% rate increases last year to combat 8.5% medical inflation) has successfully realigned revenues with claims experience. Medical stop-loss revenue growth and favourable In-force Management experience drove the beat.
Canada Wealth Accelerating
Canada underlying net income surged 23% to $427 million. Asset management gross flows and wealth sales rocketed 60% YoY to $7.37 billion. This massive acceleration was driven by large-case defined contribution sales and increased rollover volumes in Group Wealth, proving the stickiness of the domestic ecosystem.
Contradictory Data: Asia Margin Compression
A major red flag exists beneath the rosy Asia growth narrative. While the company touted a 19% increase in individual insurance sales to $862 million (driven by Hong Kong, India, and Malaysia), the New Business Contractual Service Margin (CSM) actually contracted. New business CSM fell from $299 million in Q2 2025 to $277 million in Q2 2026. Management explicitly blamed an 'increasing competitive environment primarily in Hong Kong.' Sun Life is essentially buying top-line growth at the expense of future profit margins.
MFS Retail Bleed is Accelerating
MFS remains a structural drag on organic growth. Retail net outflows more than doubled YoY, accelerating from US$5.9B in Q2 2025 to US$13.7B in Q2 2026. Institutional outflows also ticked up slightly to US$9.2B. While higher average net assets (driven by broader market performance) saved MFS earnings this quarter, the persistent capital flight is unsustainable long-term.
Corporate Debt Drag Decelerating Earnings
The Corporate segment's underlying net loss almost doubled, widening from -$62 million in Q2 2025 to -$117 million in Q2 2026. This is the direct result of higher financing costs undertaken to support the acquisition of remaining minority interests in SLC Management affiliates (BGO and Crescent). Investors need to monitor if this debt burden restricts the pace of future share buybacks.
Applied Agentic AI and Tech Integration
Sun Life is aggressively operationalizing AI. They launched a proprietary 'agentic AI' platform for tech architecture and an AI-powered concierge for SLFD advisors in Canada to speed up complex inquiries. In the U.S., a partnership with Medzown (precision medicine) uses AI clinical navigation to connect cancer patients to trials early. In 2025, health solutions and cost containment saved the U.S. segment over US$68 million.
Macro Tailwind: Public Equity Markets
Reported net income outperformed underlying net income significantly (+41% YoY vs +11% YoY) largely due to favourable macro impacts. Strong public equity market performance and improved real estate valuations boosted results across Canada and Asia, masking some operational weaknesses in asset flows.
Other KPIs
Stable and compounding. Total AUM increased $155 billion or 10% from Q2 2025, driven by market appreciation and a large public fixed income mandate funded at ABSLAMC (Solutions & Other net inflows of US$19.7B), which offset the severe MFS outflows.
Decelerating from the robust 157% seen at the end of 2025, dropping to 145%. This decline was fully expected and planned, reflecting the capital deployed to finalize the ~$2.4 billion buyouts of minority stakes in BentallGreenOak (BGO) and Crescent Capital in H1 2026. It remains comfortably above regulatory minimums.
Guidance
Accelerating past the target. Q2 2026 underlying EPS grew 13% YoY to $2.02, proving the company can easily clear its medium-term objective when the U.S. segment isn't acting as a severe drag.
Stable. The company delivered an underlying ROE of 19.1% for the quarter, marginally up from the 18.7% year-to-date average and inching closer to the ambitious 20% medium-term goal.
Key Questions
Hong Kong Margin Compression
Individual sales in Asia grew 19%, but New Business CSM contracted 7% due to the competitive environment in Hong Kong. Is this purely a pricing war, or a mix shift to lower-margin products, and when do you expect CSM growth to realign with sales growth?
MFS Floor
MFS retail outflows accelerated to US$13.7B this quarter. While active ETFs are gaining traction, they are a drop in the bucket compared to the retail bleed. What is the structural fix here, or are we just waiting for a market shift back to active management?
Pace of Buybacks Post-SLC Buyout
With the LICAT ratio settling at 145% post the BGO and Crescent buyouts, and corporate financing costs doubling, how should we think about the cadence of the 10 million share NCIB authorized in May?